Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease

References

• Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2016;12(4):459–509.
   PubMedGoogle Scholar
• Arrighi HM, Neumann PJ, Lieberburg IM, et al. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90–95.
   PubMed Web of Science ®Google Scholar
• Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759–774.
   PubMed Web of Science ®Google Scholar
• Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S51–6.
   PubMedGoogle Scholar
• Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer’s disease. Prim Care Companion J Clin Psychiatry. 2006;8(3):158–159.
   PubMedGoogle Scholar
• Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease. J Int Neuropsychol Soc. 2005;11(4):446–453.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057–1065.
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459–469.
   PubMed Web of Science ®Google Scholar
• Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399–407.
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57(4):613–620.
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559–569.
   PubMed Web of Science ®Google Scholar
• Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577–2587.
   PubMed Web of Science ®Google Scholar
• Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer’s disease. J Clin Psychopharmacol. 2002;22(6):615–620.
   PubMed Web of Science ®Google Scholar
• Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer’s disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011;11:21.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–1251.
   PubMed Web of Science ®Google Scholar
• Salloway S, Mintzer J, Cummings JL, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(6):421–432.
   PubMed Web of Science ®Google Scholar
• Statistical review(s). Donepezil 23 mg tablets drug approval package. U.S. Food and Drug Administration; 2010 [cited 2016 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000StatR.pdf
   Google Scholar
• Homma A, Atarashi H, Kubota N, et al. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer’s disease: a randomized, double-blind trial. J Alzheimers Dis. 2016;52(1):345–357.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745–752.
   PubMed Web of Science ®Google Scholar
• Sabbagh M, Cummings J, Christensen D, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013;13:56.
   PubMed Web of Science ®Google Scholar
• Medical review(s). Donepezil 23 mg tablets drug approval package. U.S. Food and Drug Administration; 2010 [cited 2016 Jun 1]. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
   Google Scholar
• Han SH, Lee JH, Kim SY, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer’s disease. Acta Neurol Scand. 2016 [cited 2016 Feb 29]. doi:10.1111/ane.12571.
   Google Scholar
• Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39–47.
   PubMed Web of Science ®Google Scholar
• Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546–53.
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Farlow MR, Meng X, et al. Evaluating high-dose rivastigmine patch in severe Alzheimer’s disease: analyses with concomitant memantine usage as a factor. Curr Alzheimer Res. 2015;12(1):53–60.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Sadowsky CH, Velting DM, et al. Evaluating response to high-dose 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease. CNS Neurosci Ther. 2015;21(6):513–519.
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther. 2008;83(1):106–114.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341.
   PubMed Web of Science ®Google Scholar
• Van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136–143.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kitamura S, Homma A, et al. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother. 2014;15(7):913–925.
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–146.
   PubMed Web of Science ®Google Scholar
• Rive B, Gauthier S, Costello S, et al. Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer’s disease. CNS Drugs. 2013;27(7):573–582.
   PubMed Web of Science ®Google Scholar
• Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–27.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289.
   PubMed Web of Science ®Google Scholar
• Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1–470.
   PubMed Web of Science ®Google Scholar
• Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s Disease. NICE Submission of Evidence: Memantine. National Institute for Health and Clinical Excellence; 2010 [cited 2016 Jun 1]. Available from: https://www.nice.org.uk/guidance/ta217/documents/alzheimers-disease-donepezil-galantamine-rivastigmine-and-memantine-review-lundbeck-uk2
   Google Scholar
• Memantine for the treatment of moderate to severe Alzheimer’s disease. NICE Submission of Evidence: Memantine. National Institute for Health and Clinical Excellence; 2010 [cited 2016 Jun 1]. Available from: https://www.nice.org.uk/guidance/TA217/documents/alzheimers-disease-donepezil-galantamine-rivastigmine-and-memantine-review-lundbeck2
   Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–89.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324.
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–478.
   PubMed Web of Science ®Google Scholar
• Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol. 2015;22(6):889–898.
   PubMed Web of Science ®Google Scholar
• Grossberg G, Alva G, Hendrix S, et al. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer’s disease: subset analysis of a randomized clinical trial. Alzheimer’s Dementia. 2014;10(4 Supplement):P450.
   Google Scholar
• Withdrawal assessment report: Memantine FGK. Committee for Medicinal Products for Human Use. European Medicines Agency; 2012 [cited 2016 Jun 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002687/WC500141943.pdf
   Google Scholar
• Clinical pharmacology and biopharmaceutics review. Memantine extended release drug approval package. U.S. Food and Drug Administration; 2010 [cited 2016 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022525Orig1s000ClinPharmR.pdf
   Google Scholar
• Bucks RS, Ashworth DL, Wilcock GK, et al. Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale. Age Ageing. 1996;25(2):113–120.
   PubMed Web of Science ®Google Scholar
• Shaw G. Two drugs are not better than one for treating moderate to severe Alzheimer disease, British investigators report: why some US neurologists don’t agree. Neurol Today. 2012;12(8):12–13.
   PubMed Web of Science ®Google Scholar
• Hendrix S, Ellison N, Stanworth S, et al. Post hoc evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD study and memantine clinical trial program. J Prev Alzheimers Dis. 2015;2(3):165–171.
   PubMedGoogle Scholar
• Tariot PN. Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer’s disease compared to continuation of donepezil or addition or substitution of memantine. Evid Based Med. 2013;18(2):62–63.
   PubMedGoogle Scholar
• Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:3.
   Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;18:5.
   Web of Science ®Google Scholar
• Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–225.
   PubMed Web of Science ®Google Scholar
• Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol. 2011;11:57.
   PubMed Web of Science ®Google Scholar
• Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–22.
   PubMed Web of Science ®Google Scholar
• Alva G, Cummings JL, Galvin JE, et al. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer’s disease. Int J Clin Pract. 2015;69(5):518–530.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Robillard A, Cohen S, et al. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Curr Med Res Opin. 2013;29(8):989–1000.
   PubMed Web of Science ®Google Scholar
• Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867–873.
   PubMedGoogle Scholar
• Hernandez RK, Farwell W, Cantor MD, et al. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc. 2009;57(11):1997–2003.
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Mamdani MM, Li P, et al. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6(9):e1000157.
   PubMed Web of Science ®Google Scholar
• Sheffrin M, Miao Y, Boscardin WJ, et al. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. J Am Geriatr Soc. 2015;63(8):1512–1518.
   PubMed Web of Science ®Google Scholar
• Hurt C, Bhattacharyya S, Burns A, et al. Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dement Geriatr Cogn Disord. 2008;26(2):138–146.
   PubMed Web of Science ®Google Scholar
• Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287(16):2090–2097.
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965–1971.
   PubMed Web of Science ®Google Scholar
• Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–445.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–545.
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–348.
   PubMed Web of Science ®Google Scholar
• Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012;7(5):e35185.
   PubMed Web of Science ®Google Scholar
• Ballard C, Thomas A, Gerry S, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer’s disease (MAIN-AD). J Am Med Dir Assoc. 2015;16(4):316–322.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357(14):1382–1392.
   PubMed Web of Science ®Google Scholar
• Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–546.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Grossberg GT, et al. Investigational drugs for treating agitation in persons with dementia. Expert Opin Investig Drugs. 2016 [cited 2016 Jun 7]. doi:10.1080/13543784.2016.1193155.
   Google Scholar
• Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Black SE, Li A, et al. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23(4):539–545.
   PubMed Web of Science ®Google Scholar
• Parsons C, Briesacher BA, Givens JL, et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253–1259.
   PubMed Web of Science ®Google Scholar
• Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med. 2008;11(5):738–745.
   PubMed Web of Science ®Google Scholar
• Shega JW, Ellner L, Lau DT, et al. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779–783.
   PubMed Web of Science ®Google Scholar
• O’Regan J, Lanctot KL, Mazereeuw G, et al. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424–31.
   PubMed Web of Science ®Google Scholar
• Herrmann N, O’Regan J, Ruthirakuhan M, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17(2):142–147.
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Thomas SK, Lin SJ, et al. Predicting time to nursing home placement based on activities of daily living scores–a modelling analysis using data on Alzheimer’s disease patients receiving rivastigmine or donepezil. J Med Econ. 2009;12(2):98–103.
   PubMedGoogle Scholar
• Howard R, McShane R, Lindesay J, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer’s disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015;14(12):1171–1181.
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006;10(5):417–429.
   PubMed Web of Science ®Google Scholar
• Rountree SD, Atri A, Lopez OL, et al. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–345.
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(5):485–491.
   PubMed Web of Science ®Google Scholar
• Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease. Expert Rev Neurother. 2012;12(1):31–37.
   PubMed Web of Science ®Google Scholar
• Riepe M, Weinman J, Osae-Larbi J, et al. Factors associated with greater adherence to and satisfaction with transdermal rivastigmine in patients with Alzheimer’s disease and their caregivers. Dement Geriatr Cogn Disord. 2015;40(1–2):107–119.
   PubMed Web of Science ®Google Scholar
• Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract. 2014;68(4):465–470.
   PubMed Web of Science ®Google Scholar
• Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer’s disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013;35(1–2):23–33.
   PubMed Web of Science ®Google Scholar
• Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56(1):1–9.
   PubMed Web of Science ®Google Scholar
• Summary Review. Donepezil 23 mg tablets drug approval package. U.S. Food and Drug Administration; 2010 [cited 2016 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf
   Google Scholar
• Cummings JL, Geldmacher D, Farlow M, et al. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294–301.
   PubMed Web of Science ®Google Scholar
• Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg (ODESA). ClinicalTrials.gov; 2015 [cited 2016 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02550665
   Google Scholar
• Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7.
   PubMed Web of Science ®Google Scholar
• Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209–221.
   PubMed Web of Science ®Google Scholar
• Karlawish JH, Klocinski JL, Merz J, et al. Caregivers’ preferences for the treatment of patients with Alzheimer’s disease. Neurology. 2000;55(7):1008–1014.
   PubMed Web of Science ®Google Scholar
• Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. 2014;15(8):791–800.
   PubMed Web of Science ®Google Scholar
• Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer’s disease. N Engl J Med. 2012;366(10):957–959.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE technology appraisal guidance 217; 2011 [cited 2016 Jun 1]. Available from: https://www.nice.org.uk/guidance/ta217/resources/donepezil-galantamine-rivastigmine-and-memantine-for-the-treatment-of-alzheimers-disease-82600254699973
   Google Scholar
• Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–607.
   PubMed Web of Science ®Google Scholar
• Assessment report: Acrescent. Committee for Medicinal Products for Human Use. European Medicines Agency; 2012 [cited 2016 Jun 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002424/WC500139831.pdf
   Google Scholar